Scilex Holding Company (Nasdaq: SCLX) Announces $20 Million Private Placement Agreement for Semnur Pharmaceuticals, with CEO Jaisim Shah Committing Full Time to Accelerate SP-102's Regulatory Approval and Commercialization for Lumbosacral Radicular Pain/Sciatica Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 21 2025
0mins
Source: Newsfilter
Investment Announcement: Scilex Holding Company and its subsidiary Semnur Pharmaceuticals have secured a $20 million private placement to fund the second Phase 3 clinical trial for SP-102, a non-opioid treatment for LRP/Sciatica.
Leadership Change: Jaisim Shah has resigned as CEO of Scilex, effective August 17, 2025, and will focus on his role as CEO of Semnur, while Henry Ji, Ph.D., has been appointed as the new CEO of Scilex.
Business Combination: The merger between Semnur and Denali Capital Acquisition Corp is expected to close in September 2025, which aims to enhance Semnur's public presence and accelerate its product development.
Product Development Focus: Semnur's lead product, SP-102, is a novel gel formulation intended for epidural administration to treat chronic radicular pain/sciatica, with plans to advance it through clinical trials.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SCLX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SCLX
About SCLX
Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Scilex Holding Approves Dividend Plan
- Dividend Plan Approval: Scilex Holding's board has approved a dividend for Semnur Pharmaceuticals' common stock, marking a proactive financial management move aimed at boosting shareholder confidence and attracting more investor interest.
- Shareholder Return Strategy: This dividend plan not only demonstrates the company's commitment to its shareholders but may also enhance stock price stability and growth by increasing shareholder returns, thereby solidifying its market position.
- Financial Health Indicator: The board's decision reflects Scilex Holding's financial health in the current economic environment, indicating the company's capability to distribute profits and enhancing market confidence in its future development.
- Market Reaction Expectations: The dividend plan is expected to have a positive impact on investors, potentially attracting more institutional investor interest, which could enhance the company's market liquidity and overall valuation.
See More
Formation of DelivMeds AI with Approximate Asset Value of $4 Billion
- Asset Value: The formation of DelivMeds AI is expected to have an approximate asset value of $4 billion, stemming from a comprehensive partnership between Datavault AI and Wellgistics Health aimed at enhancing healthcare service efficiency through blockchain and AI integration, thereby securing a competitive edge in the rapidly evolving healthcare market.
- Technology Integration and Expansion: The fully binding term sheet signed between Datavault AI and Wellgistics Health expands the PharmacyChain™ platform to include Healthcare-as-a-Service (HaaS), connecting over 6,500 pharmacies and 200 manufacturers, significantly improving the efficiency and transparency of pharmaceutical delivery.
- Innovative Healthcare Solutions: Following the acquisition of the QOLPOM patent portfolio, DelivMeds AI will leverage biometric verification and AI-driven drones to enhance pharmaceutical delivery and sample collection in rural areas, which is expected to greatly improve accessibility and compliance in healthcare services.
- Market Promotion and Collaboration: The
See More
ACEA Therapeutics to be Acquired by Phoenix Asia in $1 Billion Deal
- Deal Details: ACEA Therapeutics will sell 100% of its equity interests in ACEA Pharma to Phoenix Asia for a total transaction value of $1 billion, with Phoenix issuing 100 million new ordinary shares at $10 each, expected to close by Q2 2026, marking a significant shift towards the pharmaceutical industry.
- Stock Price Reaction: Shares of Phoenix Asia Holdings (PHOE) surged 169% following the announcement of the deal, reflecting strong market optimism and the potential for further growth in the pharmaceutical sector.
- Market Sentiment: On Stocktwits, retail sentiment around SCLX remained in the 'extremely bullish' territory, while PHOE's sentiment jumped from 'bullish' to 'extremely bullish', indicating positive investor reactions and expectations for future potential.
- Corporate Restructuring: Upon completion of the deal, Phoenix Asia will be renamed ACEA Pharma, Inc., continuing to trade on Nasdaq, with ACEA Therapeutics projected to own approximately 82% of the new entity, further solidifying its position in the pharmaceutical industry.
See More
Scilex Acquires ACEA Pharma for $1 Billion
- Acquisition Overview: Scilex's indirect subsidiary ACEA Therapeutics has entered into an agreement with Phoenix Asia Holdings to sell 100% of ACEA Pharma's equity interests at $10 per share, totaling $1 billion, with completion expected by the end of Q2 2026, marking a strategic expansion in non-opioid pain management.
- Equity Structure Change: Upon closing, ACEA Therapeutics anticipates owning approximately 82% of the newly formed ACEA Pharma, enhancing its market control and supporting future product development and commercialization efforts.
- Market Listing Plans: The newly established ACEA Pharma is expected to be listed on Nasdaq, which will not only elevate the company's market visibility but also potentially attract more investor interest in its non-opioid pain management products, further driving company growth.
- Strategic Implications: This acquisition aligns with Scilex's long-term growth strategy and will enhance its competitive position in the acute and chronic pain treatment market by integrating ACEA Pharma's R&D capabilities to meet the increasing patient demand.
See More
SCILEX HOLDING CO - ACEA THERA TO ACQUIRE APPROXIMATELY 82% OF THE CONTINUING COMPANY AFTER CLOSURE
Company Overview: Cilex Holding Co. has a significant stake in the Go-Forward Company, owning approximately 82% of it.
Recent Developments: The ownership stake was confirmed upon the closing of a recent transaction.
See More
SCILEX HOLDING CO - PHOENIX TO CHANGE NAME TO ACEA PHARMA, INC. AND PLANS TO DEBUT ON NASDAQ
- Company Name Change: SciLEx Holding Co. is set to be renamed as Acea Pharma, Inc.
- Upcoming Listing: The company is expected to list on the NASDAQ stock exchange.
See More
Scilex Holding Approves Dividend Plan
- Dividend Plan Approval: Scilex Holding's board has approved a dividend for Semnur Pharmaceuticals' common stock, marking a proactive financial management move aimed at boosting shareholder confidence and attracting more investor interest.
- Shareholder Return Strategy: This dividend plan not only demonstrates the company's commitment to its shareholders but may also enhance stock price stability and growth by increasing shareholder returns, thereby solidifying its market position.
- Financial Health Indicator: The board's decision reflects Scilex Holding's financial health in the current economic environment, indicating the company's capability to distribute profits and enhancing market confidence in its future development.
- Market Reaction Expectations: The dividend plan is expected to have a positive impact on investors, potentially attracting more institutional investor interest, which could enhance the company's market liquidity and overall valuation.
See More
Formation of DelivMeds AI with Approximate Asset Value of $4 Billion
- Asset Value: The formation of DelivMeds AI is expected to have an approximate asset value of $4 billion, stemming from a comprehensive partnership between Datavault AI and Wellgistics Health aimed at enhancing healthcare service efficiency through blockchain and AI integration, thereby securing a competitive edge in the rapidly evolving healthcare market.
- Technology Integration and Expansion: The fully binding term sheet signed between Datavault AI and Wellgistics Health expands the PharmacyChain™ platform to include Healthcare-as-a-Service (HaaS), connecting over 6,500 pharmacies and 200 manufacturers, significantly improving the efficiency and transparency of pharmaceutical delivery.
- Innovative Healthcare Solutions: Following the acquisition of the QOLPOM patent portfolio, DelivMeds AI will leverage biometric verification and AI-driven drones to enhance pharmaceutical delivery and sample collection in rural areas, which is expected to greatly improve accessibility and compliance in healthcare services.
- Market Promotion and Collaboration: The
See More
ACEA Therapeutics to be Acquired by Phoenix Asia in $1 Billion Deal
- Deal Details: ACEA Therapeutics will sell 100% of its equity interests in ACEA Pharma to Phoenix Asia for a total transaction value of $1 billion, with Phoenix issuing 100 million new ordinary shares at $10 each, expected to close by Q2 2026, marking a significant shift towards the pharmaceutical industry.
- Stock Price Reaction: Shares of Phoenix Asia Holdings (PHOE) surged 169% following the announcement of the deal, reflecting strong market optimism and the potential for further growth in the pharmaceutical sector.
- Market Sentiment: On Stocktwits, retail sentiment around SCLX remained in the 'extremely bullish' territory, while PHOE's sentiment jumped from 'bullish' to 'extremely bullish', indicating positive investor reactions and expectations for future potential.
- Corporate Restructuring: Upon completion of the deal, Phoenix Asia will be renamed ACEA Pharma, Inc., continuing to trade on Nasdaq, with ACEA Therapeutics projected to own approximately 82% of the new entity, further solidifying its position in the pharmaceutical industry.
See More
Scilex Acquires ACEA Pharma for $1 Billion
- Acquisition Overview: Scilex's indirect subsidiary ACEA Therapeutics has entered into an agreement with Phoenix Asia Holdings to sell 100% of ACEA Pharma's equity interests at $10 per share, totaling $1 billion, with completion expected by the end of Q2 2026, marking a strategic expansion in non-opioid pain management.
- Equity Structure Change: Upon closing, ACEA Therapeutics anticipates owning approximately 82% of the newly formed ACEA Pharma, enhancing its market control and supporting future product development and commercialization efforts.
- Market Listing Plans: The newly established ACEA Pharma is expected to be listed on Nasdaq, which will not only elevate the company's market visibility but also potentially attract more investor interest in its non-opioid pain management products, further driving company growth.
- Strategic Implications: This acquisition aligns with Scilex's long-term growth strategy and will enhance its competitive position in the acute and chronic pain treatment market by integrating ACEA Pharma's R&D capabilities to meet the increasing patient demand.
See More
SCILEX HOLDING CO - ACEA THERA TO ACQUIRE APPROXIMATELY 82% OF THE CONTINUING COMPANY AFTER CLOSURE
Company Overview: Cilex Holding Co. has a significant stake in the Go-Forward Company, owning approximately 82% of it.
Recent Developments: The ownership stake was confirmed upon the closing of a recent transaction.
See More
SCILEX HOLDING CO - PHOENIX TO CHANGE NAME TO ACEA PHARMA, INC. AND PLANS TO DEBUT ON NASDAQ
- Company Name Change: SciLEx Holding Co. is set to be renamed as Acea Pharma, Inc.
- Upcoming Listing: The company is expected to list on the NASDAQ stock exchange.
See More
